Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Prenylamine | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Prenylamine | hsa00072 | Synthesis and degradation of ketone bodies | 2.78E-02 | 1 | Q01581 | HMGCS1 | More | | Prenylamine | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | Prenylamine | hsa00230 | Purine metabolism | 4.60E-02 | 4 | Q13370, P36959, Q13956, P27707 | PDE3B, GMPR, PDE6H, DCK | More | | Prenylamine | hsa00240 | Pyrimidine metabolism | 4.50E-02 | 2 | P32320, P27707 | CDA, DCK | More | | Prenylamine | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 1.91E-02 | 1 | Q9NY97 | B3GNT2 | More | | Prenylamine | hsa00534 | Glycosaminoglycan biosynthesis - heparan sulfate / heparin | 4.77E-02 | 1 | Q7LGA3 | HS2ST1 | More | | Prenylamine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Prenylamine | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Prenylamine | hsa00601 | Glycosphingolipid biosynthesis - lacto and neolacto series | 3.78E-02 | 1 | Q9NY97 | B3GNT2 | More | | Prenylamine | hsa00630 | Glyoxylate and dicarboxylate metabolism | 4.46E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | | Prenylamine | hsa00670 | One carbon pool by folate | 3.99E-02 | 2 | O95954, Q99707 | FTCD, MTR | More | | Prenylamine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | Prenylamine | hsa00900 | Terpenoid backbone biosynthesis | 1.40E-02 | 1 | Q01581 | HMGCS1 | More | | Prenylamine | hsa00920 | Sulfur metabolism | 3.01E-02 | 1 | O95571 | ETHE1 | More | | Prenylamine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Prenylamine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Prenylamine | hsa01100 | Metabolic pathways | 3.95E-02 | 23 | Q9Y234, Q99707, P29218, P11310, P27707, Q13370, P36959, Q13956, P30043, Q02252, O60701, O14772, O95954, Q02318, P04406, O15466, P09960, Q9P2R7, Q9UHY7, P35573, Q13488, Q16718, Q02809 | LIPT1, MTR, IMPA1, ACADM, DCK, PDE3B, GMPR, PDE6H, BLVRB, ALDH6A1, UGDH, FPGT, FTCD, CYP27A1, GAPDH, ST8SIA5, LTA4H, SUCLA2, ENOPH1, AGL, TCIRG1, NDUFA5, PLOD1 | More | | Prenylamine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Prenylamine | hsa01210 | 2-Oxocarboxylic acid metabolism | 1.91E-02 | 1 | P50213 | IDH3A | More | | Prenylamine | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | Prenylamine | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 2.18E-02 | 2 | P49841, Q9NRA1 | GSK3B, PDGFC | More | | Prenylamine | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | | Prenylamine | hsa01524 | Platinum drug resistance | 4.45E-02 | 4 | P10415, Q13489, P78417, P43246 | BCL2, BIRC3, GSTO1, MSH2 | More | | Prenylamine | hsa02010 | ABC transporters | 1.63E-03 | 3 | P45844, P08183, Q99758 | ABCG1, ABCB1, ABCA3 | More | | Prenylamine | hsa03013 | RNA transport | 4.79E-02 | 2 | P62826, P63279 | RAN, UBE2I | More | | Prenylamine | hsa03015 | mRNA surveillance pathway | 3.62E-02 | 3 | O43148, P61326, P52298 | RNMT, MAGOH, NCBP2 | More | | Prenylamine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Prenylamine | hsa03040 | Spliceosome | 1.32E-08 | 19 | Q14562, O43143, O60508, P17844, O14776, P08579, O75940, P52298, P09651, Q15365, O75494, Q07955, Q01130, Q13243, P11142, Q9Y2W2, O95777, O43447, P61326 | DHX8, DHX15, CDC40, DDX5, TCERG1, SNRPB2, SMNDC1, NCBP2, HNRNPA1, PCBP1, FUSIP1, SFRS1, SFRS2, SFRS5, HSPA8, WBP11, LSM8, PPIH, MAGOH | More | | Prenylamine | hsa03050 | Proteasome | 5.53E-03 | 2 | P43686, P28070 | PSMC4, PSMB4 | More | | Prenylamine | hsa03320 | PPAR signaling pathway | 2.18E-02 | 2 | O00767, Q02318 | SCD, CYP27A1 | More | | Prenylamine | hsa03460 | Fanconi anemia pathway | 3.70E-03 | 3 | Q9NPI8, O60673, Q9UNA4 | FANCF, REV3L, POLI | More | | Prenylamine | hsa04014 | Ras signaling pathway | 2.62E-04 | 11 | P31751, P42338, P20827, P49767, Q13009, P17252, Q15311, P0DP23, P62873, P50151, P19174 | AKT2, PIK3CB, EFNA1, VEGFC, TIAM1, PRKCA, RALBP1, CALM1, GNB1, GNG10, PLCG1 | More | | Prenylamine | hsa04015 | Rap1 signaling pathway | 5.41E-03 | 9 | P20827, P49767, Q13009, Q08828, P51828, P31751, P0DP23, P17252, P19174 | EFNA1, VEGFC, TIAM1, ADCY1, ADCY7, AKT2, CALM1, PRKCA, PLCG1 | More | | Prenylamine | hsa04020 | Calcium signaling pathway | 1.04E-06 | 11 | P27987, Q08828, Q13557, P17252, O15399, P19174, P61073, P0DP23, P51828, P23634, P49767 | ITPKB, ADCY1, CAMK2D, PRKCA, GRIN2D, PLCG1, CXCR4, CALM1, ADCY7, ATP2B4, VEGFC | More | | Prenylamine | hsa04024 | cAMP signaling pathway | 3.01E-03 | 9 | Q08828, P51828, P31751, P0DP23, P23634, Q13557, Q13370, O15399, Q13009 | ADCY1, ADCY7, AKT2, CALM1, ATP2B4, CAMK2D, PDE3B, GRIN2D, TIAM1 | More | | Prenylamine | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | | Prenylamine | hsa04062 | Chemokine signaling pathway | 1.29E-03 | 17 | P51684, P25024, P25025, P09341, P19875, Q8NHW4, P42338, P19174, P62873, P63218, P50151, Q08828, P51828, Q13009, P14598, P42224, P31751 | CCR6, CXCR1, CXCR2, CXCL1, CXCL2, CCL4L2, PIK3CB, PLCG1, GNB1, GNG5, GNG10, ADCY1, ADCY7, TIAM1, NCF1, STAT1, AKT2 | More | | Prenylamine | hsa04064 | NF-kappa B signaling pathway | 1.67E-05 | 15 | P10415, Q13489, P51617, P14778, P01584, P29965, P19174, Q04759, P06239, O75293, Q8NHW4, P09341, P19875, Q06643, Q9NQC7 | BCL2, BIRC3, IRAK1, IL1R1, IL1B, CD40LG, PLCG1, PRKCQ, LCK, GADD45B, CCL4L2, CXCL1, CXCL2, LTB, CYLD | More | | Prenylamine | hsa04070 | Phosphatidylinositol signaling system | 5.66E-04 | 6 | P19174, P0DP23, P23743, P48426, P27987, P17252 | PLCG1, CALM1, DGKA, PIP4K2A, ITPKB, PRKCA | More | | Prenylamine | hsa04071 | Sphingolipid signaling pathway | 1.60E-03 | 9 | P17252, P21453, Q9H228, P01375, Q13510, Q13362, P10415, Q9UQC2, P01042 | PRKCA, S1PR1, EDG8, TNF, ASAH1, PPP2R5C, BCL2, GAB2, KNG1 | More | | Prenylamine | hsa04072 | Phospholipase D signaling pathway | 2.68E-03 | 12 | P31751, P42338, P43657, P25024, P25025, P19174, P17252, Q15438, Q08828, P51828, P23743, P00734 | AKT2, PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1, PRKCA, PSCD1, ADCY1, ADCY7, DGKA, F2 | More | | Prenylamine | hsa04080 | Neuroactive ligand-receptor interaction | 2.84E-03 | 7 | P28472, P21453, Q9H228, Q01726, P41968, P21730, P07550 | GABRB3, S1PR1, EDG8, MC1R, MC3R, C5AR1, ADRB2 | More | | Prenylamine | hsa04110 | Cell cycle | 6.80E-03 | 6 | P06493, O75293, P30304, P33981, P42773, P01106 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | | Prenylamine | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | Prenylamine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Prenylamine | hsa04140 | Autophagy - animal | 2.58E-02 | 7 | P31751, Q7L523, Q96RR4, O75460, P10415, Q96GC9, Q8TEV9 | AKT2, RRAGA, CAMKK2, ERN1, BCL2, TMEM49, SMCR8 | More | | Prenylamine | hsa04144 | Endocytosis | 8.99E-03 | 12 | P11142, Q9H444, O43633, O75351, Q9NZZ3, Q15438, Q14161, P14784, Q96QK1, Q9UMY4, Q9Y5X3, Q9UNH7 | HSPA8, CHMP4B, CHMP2A, VPS4B, CHMP5, PSCD1, GIT2, IL2RB, VPS35, SNX12, SNX5, SNX6 | More | | Prenylamine | hsa04145 | Phagosome | 5.56E-03 | 8 | P60709, P63261, Q15075, Q15080, P14598, Q13509, Q13488, O60603 | ACTB, ACTG1, EEA1, NCF4, NCF1, TUBB3, TCIRG1, TLR2 | More | | Prenylamine | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | | Prenylamine | hsa04151 | PI3K-Akt signaling pathway | 2.44E-04 | 23 | P42338, P43657, O43521, P27348, P20827, P49767, Q13362, P08238, P62873, P50151, P16144, O15335, Q13751, P48551, P14784, P23458, P01568, P15336, P18848, P10415, P17252, Q16513, Q6ZUJ8 | PIK3CB, P2RY5, BCL2L11, YWHAQ, EFNA1, VEGFC, PPP2R5C, HSP90AB1, GNB1, GNG10, ITGB4, CHAD, LAMB3, IFNAR2, IL2RB, JAK1, IFNA21, ATF2, ATF4, BCL2, PRKCA, PKN2, PIK3AP1 | More | | Prenylamine | hsa04210 | Apoptosis | 6.18E-03 | 3 | P07384, P60709, P63261 | CAPN1, ACTB, ACTG1 | More | | Prenylamine | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | Prenylamine | hsa04217 | Necroptosis | 2.92E-09 | 19 | P01375, P01568, P23458, P48023, Q13489, Q9NQC7, P42224, Q14765, P08238, P01584, P0C0S5, Q6FI13, Q99878, P10415, Q13557, Q9H444, O43633, Q9NZZ3, O75351 | TNF, IFNA21, JAK1, FASLG, BIRC3, CYLD, STAT1, STAT4, HSP90AB1, IL1B, H2AFZ, H2AC18; H2AC19, H2AC14, BCL2, CAMK2D, CHMP4B, CHMP2A, CHMP5, VPS4B | More | | Prenylamine | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | | Prenylamine | hsa04261 | Adrenergic signaling in cardiomyocytes | 4.46E-07 | 13 | P09493, P07550, Q08828, P51828, P22694, P31751, P18848, Q13362, P0DP23, Q13557, P17252, P10415, P23634 | TPM1, ADRB2, ADCY1, ADCY7, PRKACB, AKT2, ATF4, PPP2R5C, CALM1, CAMK2D, PRKCA, BCL2, ATP2B4 | More | | Prenylamine | hsa04360 | Axon guidance | 8.44E-04 | 8 | P61073, P16333, P20827, O95631, P17252, Q13557, P23528, P19174 | CXCR4, NCK1, EFNA1, NTN1, PRKCA, CAMK2D, CFL1, PLCG1 | More | | Prenylamine | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | Prenylamine | hsa04371 | Apelin signaling pathway | 3.08E-02 | 7 | P62873, P31751, Q08828, P51828, Q13370, Q13485, P0DP23 | GNB1, AKT2, ADCY1, ADCY7, PDE3B, SMAD4, CALM1 | More | | Prenylamine | hsa04380 | Osteoclast differentiation | 4.18E-02 | 7 | Q9NQC7, Q9UQC2, P23458, P42224, P01584, Q15080, P14598 | CYLD, GAB2, JAK1, STAT1, IL1B, NCF4, NCF1 | More | | Prenylamine | hsa04390 | Hippo signaling pathway | 2.63E-03 | 3 | P60709, P63261, O15105 | ACTB, ACTG1, SMAD7 | More | | Prenylamine | hsa04510 | Focal adhesion | 3.76E-02 | 7 | P16144, O75369, Q15942, P17252, Q13489, P10415, P49767 | ITGB4, FLNB, ZYX, PRKCA, BIRC3, BCL2, VEGFC | More | | Prenylamine | hsa04520 | Adherens junction | 1.58E-02 | 2 | P60709, P63261 | ACTB, ACTG1 | More | | Prenylamine | hsa04530 | Tight junction | 7.61E-05 | 7 | P60709, P63261, P16989, P56750, Q92974, Q14247, P60660 | ACTB, ACTG1, CSDA, CLDN17, ARHGEF2, CTTN, MYL6 | More | | Prenylamine | hsa04540 | Gap junction | 4.08E-02 | 5 | P17252, Q13509, P68371, Q08828, P51828 | PRKCA, TUBB3, TUBB2C, ADCY1, ADCY7 | More | | Prenylamine | hsa04611 | Platelet activation | 2.61E-02 | 2 | P60709, P63261 | ACTB, ACTG1 | More | | Prenylamine | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Prenylamine | hsa04613 | Neutrophil extracellular trap formation | 2.18E-03 | 7 | P04908, Q93077, P62807, O60814, P68431, O43315, Q16539 | H2AC4; H2AC8, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | | Prenylamine | hsa04620 | Toll-like receptor signaling pathway | 1.33E-02 | 5 | P51617, P01568, P31751, P42224, Q8NHW4 | IRAK1, IFNA21, AKT2, STAT1, CCL4L2 | More | | Prenylamine | hsa04621 | NOD-like receptor signaling pathway | 3.16E-02 | 9 | P01584, P08238, P23458, P42224, P01568, Q9H3M7, Q13489, P43490, P10415 | IL1B, HSP90AB1, JAK1, STAT1, IFNA21, TXNIP, BIRC3, PBEF1, BCL2 | More | | Prenylamine | hsa04623 | Cytosolic DNA-sensing pathway | 4.25E-02 | 2 | P01568, Q8NHW4 | IFNA21, CCL4L2 | More | | Prenylamine | hsa04630 | JAK-STAT signaling pathway | 1.16E-02 | 8 | P31751, P10415, P42224, P23458, P14784, P16871, Q13651, P01568 | AKT2, BCL2, STAT1, JAK1, IL2RB, IL7R, IL10RA, IFNA21 | More | | Prenylamine | hsa04640 | Hematopoietic cell lineage | 3.74E-05 | 10 | P08514, P21926, P14778, P27930, P11215, P25063, P07766, P01732, P01730, P09564 | ITGA2B, CD9, IL1R1, IL1R2, ITGAM, CD24, CD3E, CD8A, CD4, CD7 | More | | Prenylamine | hsa04650 | Natural killer cell mediated cytotoxicity | 3.09E-07 | 15 | P16298, P50591, P19174, P01375, P06239, O60880, P20963, P42338, Q02750, Q13241, P26718, O14931, P26717, Q14953, P26715 | PPP3CB, TNFSF10, PLCG1, TNF, LCK, SH2D1A, CD247, PIK3CB, MAP2K1, KLRD1, KLRK1, NCR3, KLRC2, KIR2DS5, KLRC1 | More | | Prenylamine | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | | Prenylamine | hsa04658 | Th1 and Th2 cell differentiation | 2.21E-04 | 8 | Q04759, P07766, P20963, P19174, P06239, Q9UL17, P14784, Q13761 | PRKCQ, CD3E, CD247, PLCG1, LCK, TBX21, IL2RB, RUNX3 | More | | Prenylamine | hsa04659 | Th17 cell differentiation | 1.25E-03 | 8 | Q04759, P19174, P06239, P14784, P14778, Q9UL17, P07766, P20963 | PRKCQ, PLCG1, LCK, IL2RB, IL1R1, TBX21, CD3E, CD247 | More | | Prenylamine | hsa04660 | T cell receptor signaling pathway | 3.37E-03 | 8 | Q04759, P42338, P19174, P07766, P20963, P01732, Q13191, P06239 | PRKCQ, PIK3CB, PLCG1, CD3E, CD247, CD8A, CBLB, LCK | More | | Prenylamine | hsa04662 | B cell receptor signaling pathway | 1.02E-04 | 7 | P25963, P42338, P20023, P60033, P07948, P21854, Q8N149 | NFKBIA, PIK3CB, CR2, CD81, LYN, CD72, LILRA2 | More | | Prenylamine | hsa04664 | Fc epsilon RI signaling pathway | 1.82E-02 | 3 | P42338, P07948, P09917 | PIK3CB, LYN, ALOX5 | More | | Prenylamine | hsa04666 | Fc gamma R-mediated phagocytosis | 2.78E-02 | 6 | P08575, P19174, P23528, Q9UQC2, P14598, P17252 | PTPRC, PLCG1, CFL1, GAB2, NCF1, PRKCA | More | | Prenylamine | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | | Prenylamine | hsa04670 | Leukocyte transendothelial migration | 4.07E-02 | 2 | P60709, P63261 | ACTB, ACTG1 | More | | Prenylamine | hsa04713 | Circadian entrainment | 5.61E-05 | 7 | O15399, P0DP23, Q13557, P17252, P62873, Q08828, P51828 | GRIN2D, CALM1, CAMK2D, PRKCA, GNB1, ADCY1, ADCY7 | More | | Prenylamine | hsa04714 | Thermogenesis | 3.66E-05 | 8 | Q16539, P15336, P60709, P63261, P33121, Q16718, O14521, P36542 | MAPK14, ATF2, ACTB, ACTG1, ACSL1, NDUFA5, SDHD, ATP5C1 | More | | Prenylamine | hsa04720 | Long-term potentiation | 1.79E-04 | 9 | P17252, Q13557, P16298, P0DP23, P51812, P18848, O15399, Q08828, Q02750 | PRKCA, CAMK2D, PPP3CB, CALM1, RPS6KA3, ATF4, GRIN2D, ADCY1, MAP2K1 | More | | Prenylamine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Prenylamine | hsa04724 | Glutamatergic synapse | 5.67E-04 | 9 | P48058, O15399, P43003, Q08828, P51828, P17252, P62873, P50151, P15104 | GRIA4, GRIN2D, SLC1A3, ADCY1, ADCY7, PRKCA, GNB1, GNG10, GLUL | More | | Prenylamine | hsa04725 | Cholinergic synapse | 4.42E-04 | 8 | Q08828, P51828, P17252, P62873, P18848, Q13557, P31751, P10415 | ADCY1, ADCY7, PRKCA, GNB1, ATF4, CAMK2D, AKT2, BCL2 | More | | Prenylamine | hsa04727 | GABAergic synapse | 4.08E-02 | 5 | Q08828, P51828, P62873, P46459, P17252 | ADCY1, ADCY7, GNB1, NSF, PRKCA | More | | Prenylamine | hsa04740 | Olfactory transduction | 2.61E-02 | 3 | P62873, Q13557, P0DP23 | GNB1, CAMK2D, CALM1 | More | | Prenylamine | hsa04744 | Phototransduction | 1.30E-05 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Prenylamine | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.34E-06 | 12 | P14778, P01584, Q08828, P51828, Q13557, P19174, P42338, P17252, P24723, Q04759, P0DP23, P01042 | IL1R1, IL1B, ADCY1, ADCY7, CAMK2D, PLCG1, PIK3CB, PRKCA, PRKCH, PRKCQ, CALM1, KNG1 | More | | Prenylamine | hsa04911 | Insulin secretion | 3.47E-02 | 4 | Q08828, P17252, P18848, Q13557 | ADCY1, PRKCA, ATF4, CAMK2D | More | | Prenylamine | hsa04912 | GnRH signaling pathway | 2.85E-02 | 5 | P17252, Q08828, P18848, Q13557, P0DP23 | PRKCA, ADCY1, ATF4, CAMK2D, CALM1 | More | | Prenylamine | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Prenylamine | hsa04914 | Progesterone-mediated oocyte maturation | 3.78E-03 | 9 | Q17RY0, Q08828, P51828, P31751, Q13370, Q9UJX4, P08238, P51812, Q02750 | CPEB4, ADCY1, ADCY7, AKT2, PDE3B, ANAPC5, HSP90AB1, RPS6KA3, MAP2K1 | More | | Prenylamine | hsa04915 | Estrogen signaling pathway | 3.28E-03 | 9 | P18848, Q08828, P51828, P31751, P08238, P11142, P0DP23, Q15788, P10415 | ATF4, ADCY1, ADCY7, AKT2, HSP90AB1, HSPA8, CALM1, NCOA1, BCL2 | More | | Prenylamine | hsa04916 | Melanogenesis | 2.18E-02 | 2 | P49841, Q01726 | GSK3B, MC1R | More | | Prenylamine | hsa04919 | Thyroid hormone signaling pathway | 3.20E-02 | 2 | P60709, P63261 | ACTB, ACTG1 | More | | Prenylamine | hsa04921 | Oxytocin signaling pathway | 1.77E-03 | 3 | P60660, P60709, P63261 | MYL6, ACTB, ACTG1 | More | | Prenylamine | hsa04923 | Regulation of lipolysis in adipocytes | 1.20E-03 | 7 | Q08828, P51828, P07550, Q13370, P42338, Q9Y4H2, P31751 | ADCY1, ADCY7, ADRB2, PDE3B, PIK3CB, IRS2, AKT2 | More | | Prenylamine | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | Prenylamine | hsa04925 | Aldosterone synthesis and secretion | 6.45E-04 | 7 | P18848, Q08828, P51828, P0DP23, P17252, Q13557, P23634 | ATF4, ADCY1, ADCY7, CALM1, PRKCA, CAMK2D, ATP2B4 | More | | Prenylamine | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | Prenylamine | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | Prenylamine | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | | Prenylamine | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.04E-06 | 8 | Q13485, P01584, P42224, P10415, P31751, P49767, P17252, P19174 | SMAD4, IL1B, STAT1, BCL2, AKT2, VEGFC, PRKCA, PLCG1 | More | | Prenylamine | hsa04935 | Growth hormone synthesis, secretion and action | 3.93E-02 | 6 | P19174, Q08828, P51828, P17252, P31751, P42224 | PLCG1, ADCY1, ADCY7, PRKCA, AKT2, STAT1 | More | | Prenylamine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Prenylamine | hsa04970 | Salivary secretion | 9.40E-05 | 8 | P07550, Q08828, P51828, P22694, P23634, P17252, P0DP23, P49913 | ADRB2, ADCY1, ADCY7, PRKACB, ATP2B4, PRKCA, CALM1, CAMP | More | | Prenylamine | hsa04971 | Gastric acid secretion | 1.02E-02 | 2 | P60709, P63261 | ACTB, ACTG1 | More | | Prenylamine | hsa04972 | Pancreatic secretion | 1.92E-03 | 5 | P23634, P17252, Q08828, P51828, P62491 | ATP2B4, PRKCA, ADCY1, ADCY7, RAB11A | More | | Prenylamine | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Prenylamine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | Prenylamine | hsa05014 | Amyotrophic lateral sclerosis | 2.98E-02 | 3 | P36542, P60709, P63261 | ATP5C1, ACTB, ACTG1 | More | | Prenylamine | hsa05017 | Spinocerebellar ataxia | 3.80E-03 | 8 | P17252, O75460, Q8TB72, O15399, P31751, P28070, P43686, O00232 | PRKCA, ERN1, PUM2, GRIN2D, AKT2, PSMB4, PSMC4, PSMD12 | More | | Prenylamine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | | Prenylamine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | | Prenylamine | hsa05031 | Amphetamine addiction | 3.62E-03 | 7 | O15399, P0DP23, Q13557, P22694, P18848, P17252, Q13547 | GRIN2D, CALM1, CAMK2D, PRKACB, ATF4, PRKCA, HDAC1 | More | | Prenylamine | hsa05032 | Morphine addiction | 4.08E-02 | 5 | Q08828, P51828, P62873, Q13370, P17252 | ADCY1, ADCY7, GNB1, PDE3B, PRKCA | More | | Prenylamine | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Prenylamine | hsa05100 | Bacterial invasion of epithelial cells | 1.02E-02 | 2 | P60709, P63261 | ACTB, ACTG1 | More | | Prenylamine | hsa05110 | Vibrio cholerae infection | 3.95E-03 | 2 | P60709, P63261 | ACTB, ACTG1 | More | | Prenylamine | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.78E-03 | 5 | P09341, P19875, P19174, P25024, P25025 | CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | | Prenylamine | hsa05131 | Shigellosis | 1.91E-02 | 3 | P60709, P63261, P07384 | ACTB, ACTG1, CAPN1 | More | | Prenylamine | hsa05132 | Salmonella infection | 3.99E-04 | 13 | P51617, P01584, P08238, Q96RF0, Q13489, P10415, P08575, O75369, Q13561, Q13509, P68371, P49754, Q9NP90 | IRAK1, IL1B, HSP90AB1, SNAG1, BIRC3, BCL2, PTPRC, FLNB, DCTN2, TUBB3, TUBB2C, VPS41, RAB9B | More | | Prenylamine | hsa05133 | Pertussis | 3.94E-04 | 5 | P0DP23, P01584, P23528, P09871, P51617 | CALM1, IL1B, CFL1, C1S, IRAK1 | More | | Prenylamine | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | Prenylamine | hsa05135 | Yersinia infection | 3.88E-03 | 3 | P60709, P63261, Q16513 | ACTB, ACTG1, PKN2 | More | | Prenylamine | hsa05140 | Leishmaniasis | 2.58E-02 | 5 | P14598, O60603, P25963, P29350, Q15080 | NCF1, TLR2, NFKBIA, PTPN6, NCF4 | More | | Prenylamine | hsa05143 | African trypanosomiasis | 3.56E-03 | 5 | P01375, P01584, P48023, P17252, P01042 | TNF, IL1B, FASLG, PRKCA, KNG1 | More | | Prenylamine | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | | Prenylamine | hsa05145 | Toxoplasmosis | 5.28E-05 | 9 | P51617, P10415, Q13489, P23458, P42224, P31751, P11142, P29965, Q13651 | IRAK1, BCL2, BIRC3, JAK1, STAT1, AKT2, HSPA8, CD40LG, IL10RA | More | | Prenylamine | hsa05146 | Amoebiasis | 2.05E-05 | 11 | P09341, P19875, P14778, P27930, P01375, P42338, P11215, P05089, P30679, P22694, P12814 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, PIK3CB, ITGAM, ARG1, GNA15, PRKACB, ACTN1 | More | | Prenylamine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Prenylamine | hsa05161 | Hepatitis B | 1.31E-04 | 10 | P17252, P18848, P23458, Q13485, P31751, P10415, P27348, P01568, P42224, P51617 | PRKCA, ATF4, JAK1, SMAD4, AKT2, BCL2, YWHAQ, IFNA21, STAT1, IRAK1 | More | | Prenylamine | hsa05162 | Measles | 1.74E-04 | 10 | P51617, P01568, P23458, P42224, P14784, P31751, P11142, P01584, Q9NP90, P10415 | IRAK1, IFNA21, JAK1, STAT1, IL2RB, AKT2, HSPA8, IL1B, RAB9B, BCL2 | More | | Prenylamine | hsa05163 | Human cytomegalovirus infection | 2.59E-03 | 14 | P31751, P62873, P0DP23, Q8NHW4, Q08828, P51828, P23458, P01584, P61073, P17252, Q13651, P18848, P61769, P01568 | AKT2, GNB1, CALM1, CCL4L2, ADCY1, ADCY7, JAK1, IL1B, CXCR4, PRKCA, IL10RA, ATF4, B2M, IFNA21 | More | | Prenylamine | hsa05164 | Influenza A | 7.10E-03 | 3 | P48551, P60709, P63261 | IFNAR2, ACTB, ACTG1 | More | | Prenylamine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.94E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | | Prenylamine | hsa05168 | Herpes simplex virus 1 infection | 2.45E-05 | 18 | P01568, P01584, Q9UBU9, P23458, P42224, Q07955, Q01130, Q13243, Q13489, P51617, P61769, P31751, Q13398, Q6P280, Q03923, Q9UDV6, P10415, Q14232 | IFNA21, IL1B, NXF1, JAK1, STAT1, SFRS1, SFRS2, SFRS5, BIRC3, IRAK1, B2M, AKT2, ZNF211, ZNF529, ZNF85, ZNF212, BCL2, EIF2B1 | More | | Prenylamine | hsa05170 | Human immunodeficiency virus 1 infection | 1.80E-06 | 17 | P31751, Q02750, P62873, P62879, P16298, P0DP23, P61073, Q05397, P17252, P61769, P01568, P51617, P19174, P23528, P10415, Q9Y6Q5, P20333 | AKT2, MAP2K1, GNB1, GNB2, PPP3CB, CALM1, CXCR4, PTK2, PRKCA, B2M, IFNA21, IRAK1, PLCG1, CFL1, BCL2, AP1M2, TNFRSF1B | More | | Prenylamine | hsa05200 | Pathways in cancer | 4.30E-09 | 28 | P23458, P08238, P42224, P19174, Q15311, P17252, P43246, Q13485, P14923, P10415, Q13489, P49767, P31751, Q08828, P51828, P62873, P61073, P78417, O75293, Q15788, P0DP23, Q13557, O43521, P01568, P14784, P16871, P00734, P01042 | JAK1, HSP90AB1, STAT1, PLCG1, RALBP1, PRKCA, MSH2, SMAD4, JUP, BCL2, BIRC3, VEGFC, AKT2, ADCY1, ADCY7, GNB1, CXCR4, GSTO1, GADD45B, NCOA1, CALM1, CAMK2D, BCL2L11, IFNA21, IL2RB, IL7R, F2, KNG1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P0DP23 | CALM1 | Calmodulin-1 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 0.822 | P0DP24 | CALM2 | Calmodulin-2 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 0.738 | P0DP23 | CALM1 | Calmodulin-1 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.775 | P0DP25 | CALM3 | Calmodulin-3 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.775 | P0DP24 | CALM2 | Calmodulin-2 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 0.775 | P0DP23 | CALM1 | Calmodulin-1 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.775 | P0DP25 | CALM3 | Calmodulin-3 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.775 | P0DP24 | CALM2 | Calmodulin-2 | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.775 | P0DP23 | CALM1 | Calmodulin-1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.744 | P0DP25 | CALM3 | Calmodulin-3 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.744 | P0DP24 | CALM2 | Calmodulin-2 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.744 | P0DP23 | CALM1 | Calmodulin-1 | Q15311 | RALBP1 | RalA-binding protein 1 | 0.858 | P0DP23 | CALM1 | Calmodulin-1 | P17252 | PRKCA | Protein kinase C alpha type | -0.776 | P0DP25 | CALM3 | Calmodulin-3 | P17252 | PRKCA | Protein kinase C alpha type | -0.776 | P0DP24 | CALM2 | Calmodulin-2 | P17252 | PRKCA | Protein kinase C alpha type | -0.776 | P0DP23 | CALM1 | Calmodulin-1 | P43246 | MSH2 | DNA mismatch repair protein Msh2 | 0.944 | P0DP25 | CALM3 | Calmodulin-3 | P43246 | MSH2 | DNA mismatch repair protein Msh2 | 0.944 | P0DP24 | CALM2 | Calmodulin-2 | P43246 | MSH2 | DNA mismatch repair protein Msh2 | 0.944 | P0DP23 | CALM1 | Calmodulin-1 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | 0.777 | P0DP25 | CALM3 | Calmodulin-3 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | 0.777 | P0DP24 | CALM2 | Calmodulin-2 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | 0.777 | P0DP23 | CALM1 | Calmodulin-1 | P14923 | JUP | Junction plakoglobin | -0.852 | P0DP25 | CALM3 | Calmodulin-3 | P14923 | JUP | Junction plakoglobin | -0.852 | P0DP24 | CALM2 | Calmodulin-2 | P14923 | JUP | Junction plakoglobin | -0.852 | P0DP23 | CALM1 | Calmodulin-1 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | -0.772 | P0DP25 | CALM3 | Calmodulin-3 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | -0.772 | P0DP24 | CALM2 | Calmodulin-2 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | -0.772 | P0DP23 | CALM1 | Calmodulin-1 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.8 | P0DP25 | CALM3 | Calmodulin-3 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.8 | P0DP24 | CALM2 | Calmodulin-2 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.8 | P0DP23 | CALM1 | Calmodulin-1 | P49767 | VEGFC | Vascular endothelial growth factor C | -0.84 | P0DP25 | CALM3 | Calmodulin-3 | P49767 | VEGFC | Vascular endothelial growth factor C | -0.84 | P0DP24 | CALM2 | Calmodulin-2 | P49767 | VEGFC | Vascular endothelial growth factor C | -0.84 | P0DP23 | CALM1 | Calmodulin-1 | P31751 | AKT2 | RAC-beta serine/threonine-protein kinase | 0.761 | P0DP23 | CALM1 | Calmodulin-1 | Q08828 | ADCY1 | Adenylate cyclase type 1 | 0.725 | P0DP24 | CALM2 | Calmodulin-2 | Q08828 | ADCY1 | Adenylate cyclase type 1 | 0.711 | P0DP23 | CALM1 | Calmodulin-1 | P51828 | ADCY7 | Adenylate cyclase type 7 | 0.719 | P0DP23 | CALM1 | Calmodulin-1 | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.853 | P0DP25 | CALM3 | Calmodulin-3 | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.853 | P0DP24 | CALM2 | Calmodulin-2 | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.853 | P0DP24 | CALM2 | Calmodulin-2 | P61073 | CXCR4 | C-X-C chemokine receptor type 4 | 0.759 | P0DP23 | CALM1 | Calmodulin-1 | P78417 | GSTO1 | Glutathione S-transferase omega-1 | -0.804 | P0DP25 | CALM3 | Calmodulin-3 | P78417 | GSTO1 | Glutathione S-transferase omega-1 | -0.804 | P0DP24 | CALM2 | Calmodulin-2 | P78417 | GSTO1 | Glutathione S-transferase omega-1 | -0.804 | P0DP23 | CALM1 | Calmodulin-1 | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | -0.853 | P0DP25 | CALM3 | Calmodulin-3 | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | -0.853 | P0DP24 | CALM2 | Calmodulin-2 | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | -0.853 | P0DP24 | CALM2 | Calmodulin-2 | Q15788 | NCOA1 | Nuclear receptor coactivator 1 | 0.731 | P0DP23 | CALM1 | Calmodulin-1 | P0DP23 | CALM1 | Calmodulin-1 | 1 | P0DP25 | CALM3 | Calmodulin-3 | P0DP23 | CALM1 | Calmodulin-1 | 1 | P0DP24 | CALM2 | Calmodulin-2 | P0DP23 | CALM1 | Calmodulin-1 | 1 | P0DP24 | CALM2 | Calmodulin-2 | Q13557 | CAMK2D | Calcium/calmodulin-dependent protein kinase type II subunit delta | 0.786 | P0DP24 | CALM2 | Calmodulin-2 | O43521 | BCL2L11 | Bcl-2-like protein 11 | 0.75 | P0DP23 | CALM1 | Calmodulin-1 | P01568 | IFNA21 | Interferon alpha-21 | -0.852 | P0DP25 | CALM3 | Calmodulin-3 | P01568 | IFNA21 | Interferon alpha-21 | -0.852 | P0DP24 | CALM2 | Calmodulin-2 | P01568 | IFNA21 | Interferon alpha-21 | -0.852 | P0DP23 | CALM1 | Calmodulin-1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.801 | P0DP25 | CALM3 | Calmodulin-3 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.801 | P0DP24 | CALM2 | Calmodulin-2 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.801 | P0DP23 | CALM1 | Calmodulin-1 | P16871 | IL7R | Interleukin-7 receptor subunit alpha | 0.718 | P0DP23 | CALM1 | Calmodulin-1 | P00734 | F2 | Prothrombin | -0.738 | P0DP23 | CALM1 | Calmodulin-1 | P01042 | KNG1 | Kininogen-1 | -0.71 | P0DP25 | CALM3 | Calmodulin-3 | P01042 | KNG1 | Kininogen-1 | -0.71 | P0DP24 | CALM2 | Calmodulin-2 | P01042 | KNG1 | Kininogen-1 | -0.71 |
| Prenylamine | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Prenylamine | hsa05204 | Chemical carcinogenesis | 2.59E-04 | 4 | P00325, P78417, P11712, P33260 | ADH1B, GSTO1, CYP2C9, CYP2C18 | More | | Prenylamine | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | Prenylamine | hsa05206 | MicroRNAs in cancer | 4.07E-02 | 2 | P15311, P63279 | VIL2, UBE2I | More | | Prenylamine | hsa05212 | Pancreatic cancer | 5.55E-03 | 6 | P31751, Q15311, P23458, P42224, Q13485, O75293 | AKT2, RALBP1, JAK1, STAT1, SMAD4, GADD45B | More | | Prenylamine | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | | Prenylamine | hsa05214 | Glioma | 1.87E-05 | 6 | P0DP23, Q13557, P17252, P31751, P19174, O75293 | CALM1, CAMK2D, PRKCA, AKT2, PLCG1, GADD45B | More | | Prenylamine | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | | Prenylamine | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | | Prenylamine | hsa05225 | Hepatocellular carcinoma | 4.07E-02 | 2 | P60709, P63261 | ACTB, ACTG1 | More | | Prenylamine | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | | Prenylamine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2.99E-04 | 8 | P42338, P19174, P07766, P20963, P06239, Q04759, Q9HC35, P01730 | PIK3CB, PLCG1, CD3E, CD247, LCK, PRKCQ, EML4, CD4 | More | | Prenylamine | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | | Prenylamine | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Prenylamine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Prenylamine | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | | Prenylamine | hsa05340 | Primary immunodeficiency | 8.85E-05 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | | Prenylamine | hsa05410 | Hypertrophic cardiomyopathy | 1.02E-02 | 2 | P60709, P63261 | ACTB, ACTG1 | More | | Prenylamine | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 8.96E-03 | 2 | P60709, P63261 | ACTB, ACTG1 | More | | Prenylamine | hsa05414 | Dilated cardiomyopathy | 1.73E-02 | 2 | P60709, P63261 | ACTB, ACTG1 | More | | Prenylamine | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | | Prenylamine | hsa05416 | Viral myocarditis | 8.96E-03 | 2 | P60709, P63261 | ACTB, ACTG1 | More | | Prenylamine | hsa05418 | Fluid shear stress and atherosclerosis | 3.64E-03 | 8 | P14598, P78417, P60709, P63261, P10415, P0DP23, P08238, Q92974 | NCF1, GSTO1, ACTB, ACTG1, BCL2, CALM1, HSP90AB1, ARHGEF2 | More | | |